2016
DOI: 10.1371/journal.pone.0156439
|View full text |Cite
|
Sign up to set email alerts
|

Topoisomerase 1 Regulates Gene Expression in Neurons through Cleavage Complex-Dependent and -Independent Mechanisms

Abstract: Topoisomerase 1 (TOP1) inhibitors, including camptothecin and topotecan, covalently trap TOP1 on DNA, creating cleavage complexes (cc’s) that must be resolved before gene transcription and DNA replication can proceed. We previously found that topotecan reduces the expression of long (>100 kb) genes and unsilences the paternal allele of Ube3a in neurons. Here, we sought to evaluate overlap between TOP1cc-dependent and -independent gene regulation in neurons. To do this, we utilized Top1 conditional knockout mic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
42
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 38 publications
(46 citation statements)
references
References 52 publications
4
42
0
Order By: Relevance
“…Moreover, Ube3a expression was restored in the topotecan treated but not in the Top1 ‐deleted neurons. The data from these authors also suggest that topotecan inhibits topoisomerase type I by binding to both topoisomerase type I and DNA, forming a topoisomerase type I cleavage complex [Mabb et al, ]. These data raise the concern that the systemic use of topoisomerase inhibitors such as topotecan for the treatment of AS may result in unintended off‐target effects due to the repression of many different long genes and possibly over‐expression of the shorter genes [Plasschaert and Bartolomei, ].…”
Section: Resultsmentioning
confidence: 99%
“…Moreover, Ube3a expression was restored in the topotecan treated but not in the Top1 ‐deleted neurons. The data from these authors also suggest that topotecan inhibits topoisomerase type I by binding to both topoisomerase type I and DNA, forming a topoisomerase type I cleavage complex [Mabb et al, ]. These data raise the concern that the systemic use of topoisomerase inhibitors such as topotecan for the treatment of AS may result in unintended off‐target effects due to the repression of many different long genes and possibly over‐expression of the shorter genes [Plasschaert and Bartolomei, ].…”
Section: Resultsmentioning
confidence: 99%
“…Topotecan was identified as an upstream regulatory pathway because it inhibits the topoisomerases that long genes depend on for their transcription [202][203][204][205][206][207] . It follows that the genes most affected by topotecan administration are long genes, which have a clear overlap given the length of FMRP target mRNAs and the genes encoding them.…”
Section: Loss Of Function Of Fmrp Causes Altered Behavior and Cognitimentioning
confidence: 99%
“…Recent studies suggest that transcriptional stress-driven DNA damage is also prevalent in postmitotic neurons and has the potential to disrupt genes that neurons depend on most 2 . We recently identified TOP1 as a key transcriptional regulator in postmitotic neurons 23,24 . TOP1 relieves DNA supercoiling generated during transcription by catalyzing a single-strand DNA cleavage 22 .…”
mentioning
confidence: 99%